Medios AG (0QB4.L)

14.36 +0.11 (+0.75%) At close: 05:48PM BST

Medios AG

Heidestrasse 9
Berlin 10557
Germany
49 30 232 5668 00
https://www.medios.ag

Sector(s): 
Industry: 
Full-time employees: 333

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Yann Samson	Chairman of Supervisory Board & Sustainability Officer	90k	N/A	1973
Mr. Matthias Gaertner	CEO & Chairman of the Executive Board	514k	N/A	1967
Mr. Falk Neukirch	CFO & Member of Executive Board	450k	N/A	1971
Mr. Christoph Prußeit	Chief Innovation Officer & Member of Executive Board	431k	N/A	1988
Ms. Mi-Young Miehler	COO & Member of Executive Board	433k	N/A	1969
Claudia Nickolaus	Head of Investor & Public Relations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment includes cytostatic infusion preparations, antibody therapies, virostatic and antibiotic medications, parenteral nutrition solutions, and investigational medicinal products. Medios AG was founded in 2016 and is headquartered in Berlin, Germany.

Corporate governance

Medios AG’s ISS governance QualityScore as of 1 April 2024 is 1. The pillar scores are Audit: 2; Board: 2; Shareholder rights: 1; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.